期刊
ACS NANO
卷 5, 期 6, 页码 4919-4926出版社
AMER CHEMICAL SOC
DOI: 10.1021/nn201010q
关键词
triggered drug release; nanocarrier; glioma; cancer; nanotechnology
类别
资金
- National Science Foundation [BES 0756567]
- Georgia Cancer Coalition
- Directorate For Engineering
- Div Of Chem, Bioeng, Env, & Transp Sys [0756567] Funding Source: National Science Foundation
Delivery cif chemotherapeutic agents after encapsulation in nanocarriers such as liposomes diminishes side-effects, as PEGylated nanocarrier pharmacokinetics decrease dosing to healthy tissues and accumulate in tumors due to the enhanced permeability and retention effect. Once in the tumor, however, dosing of the chemotherapeutic to tumor cells is limited potentially by the rate of release from the carriers and the size-constrained, poor diffusivity of nanocarriers in tumor interstitium. Here, we report the design and fabrication of a thermosensitive liposomal nanocarder that maintains its encapsulation stability with a high concentration of doxorubicin payload, thereby minimizing leak and attendant toxicity. When used synergistically with PEGylated gold nanorods and near-infrared stimulation, remote triggered release of doxorubicin from thermosensitive liposomes was achieved in a mouse tumor model of human glioblastoma (U87), resulting in a. significant increase in efficacy when compared to nontriggered or nonthermosensitive PEGylated liposomes. This enhancement in efficacy is attributed to increase in tumor-site apoptosis, as was evident from noninvasive apoptosis imaging using Annexin-Vivo 750 probe. This strategy afford; remotely triggered control of tumor dosing of nanocarrier-encapsulated doxorubicin without sacrificing the ability to differentially dose drugs to tumors via the enhanced permeation and retention effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据